CL2013003078A1 - Uso de una combinación farmacéutica que comprende el compuesto 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetiletil)piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (s) pirrolidin-1,2-dicarboxílico y el inhibidor de mtor everolimus para tratar cáncer de mama; y uso de la composición farmacéutica - Google Patents

Uso de una combinación farmacéutica que comprende el compuesto 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetiletil)piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (s) pirrolidin-1,2-dicarboxílico y el inhibidor de mtor everolimus para tratar cáncer de mama; y uso de la composición farmacéutica

Info

Publication number: CL2013003078A1
Authority: CL; Chile
Prior art keywords: amide; dimethylethyl; thiazol; pyrrolidin; trifluoro
Prior art date: 2011-04-25

Application number

CL2013003078A

Other languages

English (en)

Inventor

Xizhong Huang

Carlos Garcia-Echeverria

Christine Fritsch

Sauveur-Michel Maira

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-25

Filing date

2013-10-24

Publication date

2014-05-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46018130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003078(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-10-24 Application filed by Novartis Ag filed Critical Novartis Ag

2014-05-30 Publication of CL2013003078A1 publication Critical patent/CL2013003078A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Neurology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

CL2013003078A 2011-04-25 2013-10-24 Uso de una combinación farmacéutica que comprende el compuesto 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetiletil)piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (s) pirrolidin-1,2-dicarboxílico y el inhibidor de mtor everolimus para tratar cáncer de mama; y uso de la composición farmacéutica CL2013003078A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161478572P	2011-04-25	2011-04-25

Publications (1)

Publication Number	Publication Date
CL2013003078A1 true CL2013003078A1 (es)	2014-05-30

Family

ID=46018130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013003078A CL2013003078A1 (es)	2011-04-25	2013-10-24	Uso de una combinación farmacéutica que comprende el compuesto 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetiletil)piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (s) pirrolidin-1,2-dicarboxílico y el inhibidor de mtor everolimus para tratar cáncer de mama; y uso de la composición farmacéutica

Country Status (26)

Country	Link
US (3)	US20140066474A1 (es)
EP (1)	EP2701703A1 (es)
JP (2)	JP6086902B2 (es)
KR (1)	KR101925656B1 (es)
CN (1)	CN103491955B (es)
AR (1)	AR086481A1 (es)
AU (2)	AU2012250010A1 (es)
BR (1)	BR112013027486A2 (es)
CA (1)	CA2833962A1 (es)
CL (1)	CL2013003078A1 (es)
CO (1)	CO6801759A2 (es)
EA (1)	EA025948B1 (es)
EC (1)	ECSP13012994A (es)
GT (1)	GT201300263A (es)
IL (1)	IL229008A (es)
MA (1)	MA35038B1 (es)
MX (1)	MX2013012385A (es)
NZ (1)	NZ615593A (es)
PE (1)	PE20140601A1 (es)
PH (1)	PH12013502077A1 (es)
SG (1)	SG193919A1 (es)
TN (1)	TN2013000392A1 (es)
TW (1)	TWI602567B (es)
UA (1)	UA110961C2 (es)
WO (1)	WO2012148846A1 (es)
ZA (1)	ZA201306973B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112014010233A2 (pt) *	2011-11-02	2017-04-18	Novartis Ag	derivados de 2-carboxamida cicloamino ureia para uso no tratamento de doenças dependentes de vegf
CN105246482A (zh) *	2013-03-15	2016-01-13	因特利凯有限责任公司	激酶抑制剂的组合及其用途
MX2016006316A (es) *	2013-11-13	2016-07-26	Novartis Ag	Inhibidores de mtor para potenciar la respuesta inmunitaria.
US20170165246A1 (en) *	2014-02-11	2017-06-15	Novartis Ag	Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
WO2015148626A1 (en) *	2014-03-26	2015-10-01	Millennium Pharmaceuticals, Inc.	Treatment of fibrotic disorders
MX2017004359A (es) *	2014-10-03	2017-06-23	Novartis Ag	Composiciones farmaceuticas que comprenden alpelisib.
US20160339030A1 (en) *	2015-05-19	2016-11-24	University Of Maryland, Baltimore	Treatment agents for inhibiting hiv and cancer in hiv infected patients
JP6691337B2 (ja) *	2016-02-29	2020-04-28	学校法人北里研究所	膀胱癌患者の予後を予測するための方法
GB202010627D0 (en) *	2020-07-10	2020-08-26	Qbd (Qs-Ip) Ltd	Blocking method

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT98990A (pt)	1990-09-19	1992-08-31	American Home Prod	Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en)	1991-04-01	1992-06-09	American Home Products Corporation	Silyl ethers of rapamycin
US5100883A (en)	1991-04-08	1992-03-31	American Home Products Corporation	Fluorinated esters of rapamycin
US5118678A (en)	1991-04-17	1992-06-02	American Home Products Corporation	Carbamates of rapamycin
US5118677A (en)	1991-05-20	1992-06-02	American Home Products Corporation	Amide esters of rapamycin
US5151413A (en)	1991-11-06	1992-09-29	American Home Products Corporation	Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en)	1991-12-03	1992-01-29	Smithkline Beecham Plc	Novel compound
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
ZA935111B (en)	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
US5256790A (en)	1992-08-13	1993-10-26	American Home Products Corporation	27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5258389A (en)	1992-11-09	1993-11-02	Merck & Co., Inc.	O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
JP4105761B2 (ja)	1993-11-19	2008-06-25	アボット・ラボラトリーズ	ラパミシン（マクロライド）の半合成類似体免疫調節剤
ATE191218T1 (de)	1993-12-17	2000-04-15	Novartis Ag	Rapamycin-derivate als immunosuppressoren
CZ292233B6 (cs)	1995-06-09	2003-08-13	Novartis Ag	Deriváty rapamycinu a jejich použití jako léčiv
WO1998002441A2 (en)	1996-07-12	1998-01-22	Ariad Pharmaceuticals, Inc.	Non immunosuppressive antifungal rapalogs
AU783158B2 (en)	1999-08-24	2005-09-29	Ariad Pharmaceuticals, Inc.	28-epirapalogs
AR044519A1 (es) *	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
EA015922B1 (ru) *	2005-11-14	2011-12-30	Ариад Фармасьютикалз, Инк.	ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
MX2011004585A (es) *	2008-10-31	2011-06-01	Novartis Ag	Combinacion de un inhibidor de fosfatidilinositol-3-cinasa (p13k) y un inhibidor de mtor.

2012
- 2012-04-23 EP EP12717568.5A patent/EP2701703A1/en not_active Withdrawn
- 2012-04-23 CA CA2833962A patent/CA2833962A1/en not_active Abandoned
- 2012-04-23 BR BR112013027486A patent/BR112013027486A2/pt not_active Application Discontinuation
- 2012-04-23 CN CN201280020528.4A patent/CN103491955B/zh not_active Expired - Fee Related
- 2012-04-23 KR KR1020137027718A patent/KR101925656B1/ko not_active Expired - Fee Related
- 2012-04-23 AR ARP120101389A patent/AR086481A1/es unknown
- 2012-04-23 UA UAA201311138A patent/UA110961C2/uk unknown
- 2012-04-23 SG SG2013070461A patent/SG193919A1/en unknown
- 2012-04-23 JP JP2014508463A patent/JP6086902B2/ja not_active Expired - Fee Related
- 2012-04-23 WO PCT/US2012/034647 patent/WO2012148846A1/en not_active Ceased
- 2012-04-23 MA MA36325A patent/MA35038B1/fr unknown
- 2012-04-23 US US14/113,316 patent/US20140066474A1/en not_active Abandoned
- 2012-04-23 PH PH1/2013/502077A patent/PH12013502077A1/en unknown
- 2012-04-23 MX MX2013012385A patent/MX2013012385A/es unknown
- 2012-04-23 AU AU2012250010A patent/AU2012250010A1/en not_active Abandoned
- 2012-04-23 PE PE2013002391A patent/PE20140601A1/es not_active Application Discontinuation
- 2012-04-23 NZ NZ615593A patent/NZ615593A/en not_active IP Right Cessation
- 2012-04-23 EA EA201391565A patent/EA025948B1/ru not_active IP Right Cessation
- 2012-04-24 TW TW101114591A patent/TWI602567B/zh not_active IP Right Cessation
2013
- 2013-09-17 ZA ZA2013/06973A patent/ZA201306973B/en unknown
- 2013-09-27 TN TNP2013000392A patent/TN2013000392A1/fr unknown
- 2013-10-21 IL IL229008A patent/IL229008A/en active IP Right Grant
- 2013-10-24 CL CL2013003078A patent/CL2013003078A1/es unknown
- 2013-10-24 CO CO13252726A patent/CO6801759A2/es not_active Application Discontinuation
- 2013-10-25 GT GT201300263A patent/GT201300263A/es unknown
- 2013-10-25 EC ECSP13012994 patent/ECSP13012994A/es unknown
2016
- 2016-04-14 AU AU2016202372A patent/AU2016202372B2/en not_active Ceased
- 2016-10-27 US US15/335,957 patent/US20170095463A1/en not_active Abandoned
- 2016-11-18 JP JP2016224893A patent/JP2017061527A/ja active Pending
2017
- 2017-09-26 US US15/715,865 patent/US20180085362A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX2013012385A (es)	2013-11-04
KR20140012147A (ko)	2014-01-29
JP2017061527A (ja)	2017-03-30
CA2833962A1 (en)	2012-11-01
EP2701703A1 (en)	2014-03-05
CN103491955B (zh)	2015-12-23
KR101925656B1 (ko)	2018-12-05
MA35038B1 (fr)	2014-04-03
EA025948B1 (ru)	2017-02-28
WO2012148846A1 (en)	2012-11-01
ZA201306973B (en)	2014-06-25
JP2014513097A (ja)	2014-05-29
GT201300263A (es)	2015-11-24
UA110961C2 (uk)	2016-03-10
EA201391565A1 (ru)	2014-02-28
CO6801759A2 (es)	2013-11-29
TW201244716A (en)	2012-11-16
NZ615593A (en)	2015-05-29
SG193919A1 (en)	2013-11-29
BR112013027486A2 (pt)	2017-02-14
PE20140601A1 (es)	2014-05-24
AR086481A1 (es)	2013-12-18
ECSP13012994A (es)	2013-12-31
PH12013502077A1 (en)	2013-12-16
US20170095463A1 (en)	2017-04-06
JP6086902B2 (ja)	2017-03-01
IL229008A0 (en)	2013-12-31
US20140066474A1 (en)	2014-03-06
TN2013000392A1 (en)	2015-01-20
AU2012250010A1 (en)	2013-10-10
IL229008A (en)	2017-11-30
TWI602567B (zh)	2017-10-21
AU2016202372A1 (en)	2016-05-05
CN103491955A (zh)	2014-01-01
AU2016202372B2 (en)	2017-07-20
US20180085362A1 (en)	2018-03-29

Publication	Publication Date	Title
CL2013003078A1 (es)	2014-05-30	Uso de una combinación farmacéutica que comprende el compuesto 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetiletil)piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (s) pirrolidin-1,2-dicarboxílico y el inhibidor de mtor everolimus para tratar cáncer de mama; y uso de la composición farmacéutica
LTC2331537I2 (lt)	2022-01-10	1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamido dariniai, kaip fosfatidilinozitolio 3-kinazės (pi3k) inhibitoriai, naudingi proliferacinių ligų gydyme
IL268984B (en)	2021-04-29	Derivatives of oxyntomodulin and a pharmaceutical preparation containing them for the treatment of obesity
BR112014016287A2 (pt)	2017-07-04	composto, composição farmacêutica, método para aumentar a inclusão de exon 7 de smn2, método para aumentar a quantidade de proteína, método para o tratamento de sma
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
MX2012006233A (es)	2012-07-03	Nuevos compuestos de espiropiperidina.
ECSP12011799A (es)	2012-07-31	Compuestos de espiropiperidina y uso farmacéutico de los mismos
BR112013023175A2 (pt)	2016-12-13	composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto
BR112014010206A2 (pt)	2017-05-16	composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
CL2011001299A1 (es)	2012-01-13	Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer.
CL2009000483A1 (es)	2010-02-19	Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
BR112014010179A8 (pt)	2018-01-09	composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BR112014011671A2 (pt)	2017-05-30	composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
ES2654908T8 (es)	2018-04-11	Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica
BR112015003332A2 (pt)	2017-09-26	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt)	2018-04-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
EP2771321A4 (en)	2015-04-08	HYDROXAMATE DERIVATIVES FOR HDAC INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
CL2012003548A1 (es)	2013-09-06	Composicion farmaceutica de liberacion modificada que comprende esferas de liberacion inmediata y esferas de liberacion demorada de acido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxilico (febuxostat), inhibidor selectivo de xantina oxidorreductasa; forma de dosificacion; y metodo de tratamiento para gota, entre otros.
CL2014000149A1 (es)	2014-09-05	Metodo para sintetizar n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil) fenil)]acetamida y mesilato monohidrato cristalino del mismo; composicion farmaceutica que lo contiene; combinacion farmaceutica; uso en el tratamiento y/o profilaxis de una infeccion por virus herpes simplex.
EP3069720A4 (en)	2017-06-21	Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
BR112014006420A2 (pt)	2017-04-11	compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia
BR112012021476A2 (pt)	2019-09-24	composto, processo para preparação do composto, composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz do composto e emprego de tal composto
MX2014002471A (es)	2014-03-27	Combinaciones sinergicas de los inhibidores de p13k y mek.
MX2015017629A (es)	2016-04-15	Combinaciones farmaceuticas.